湿疹治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療別、流通チャネル別、地域別、競合別、2020-2030年

湿疹治療薬の世界市場規模は2024年に132億5,000万米ドルとなり、2030年までのCAGRは7.46%で、予測期間中に目覚ましい成長を遂げると予測されています。

湿疹治療薬世界市場は、炎症、かゆみ、赤みを特徴とする慢性皮膚疾患である湿疹の治療に特化した医薬品およびヘルスケア分野を指します。この市場には、湿疹の症状を緩和し、状態を管理するために設計された、外用クリーム、軟膏、内服薬、生物学的製剤を含む様々な製品が含まれます。全米湿疹協会の推計によると、3,160万人のアメリカ人が湿疹を患っており、公害、ライフスタイルの変化、化学物質への暴露などにより、その数は増加すると予想されています。このような有病率の増加は、効果的な治療に対する需要を促進し、湿疹治療薬市場の拡大に拍車をかけています。より多くの人々が緩和を求めているため、製薬会社はこの慢性皮膚疾患に対処するための革新的なソリューションに投資しています。

市場促進要因

湿疹の有病率の上昇

主な市場課題

多様な患者層

主要市場動向

治療に革命をもたらす生物学的製剤

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の湿疹治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療（抗生物質、抗ヒスタミン薬、カルシニューリン阻害剤、コルチコステロイド、皮膚軟化剤および保湿剤、免疫調節剤、インターロイキン阻害剤）
  • 流通チャネル別（病院・クリニック、オンライン薬局、小売薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療別
  • 流通チャネル別
  • 地域別

第6章 北米の湿疹治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の湿疹治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の湿疹治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の湿疹治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの湿疹治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• サノフィSA
  • 事業概要
  • 製品ラインナップ
  • 最近の動向
  • 財務状況（報告通り）
  • 主要人物
  • SWOT分析
• アンコール皮膚科
• アッヴィ株式会社
• Fホフマン・ラ・ロシュAG
• ノバルティスAG
• リジェネロン・ファーマシューティカルズ
• アステラス製薬株式会社
• GSK株式会社
• アストラゼネカ
• ファイザー株式会社

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Eczema Therapeutics Market was valued at USD 13.25 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.46% through 2030. The Global Eczema Therapeutics Market refers to the pharmaceutical and healthcare sector dedicated to treating eczema, a chronic skin condition characterized by inflammation, itching, and redness. This market encompasses various products, including topical creams, ointments, oral medications, and biologics, designed to alleviate eczema symptoms and manage the condition. According to the National Eczema Association estimates that 31.6 million Americans have eczema, with cases expected to rise due to pollution, lifestyle changes, and chemical exposure. This growing prevalence is driving demand for effective treatments, fueling the expansion of the eczema therapeutics market. As more people seek relief, pharmaceutical companies are investing in innovative solutions to address this chronic skin condition.

Key Market Drivers

Rising Prevalence of Eczema

The most apparent way in which the rising prevalence of eczema boosts the growth of the eczema therapeutics market is through the expanding patient population. Eczema affects people of all ages, from infants to adults, and its incidence has been steadily climbing. This larger pool of potential patients translates into a growing demand for effective treatments, thereby driving market growth. For instance, according to the National Eczema Association reports that eczema affects over 30 million Americans, with a prevalence of 10%-20% in children and 2%-5% in adults, highlighting its widespread impact and the need for effective treatments across different age groups.

As eczema continues to affect a greater number of individuals and families, awareness of the condition has risen significantly. Patients and their caregivers are increasingly seeking medical advice and treatment options. This growing awareness contributes to early diagnosis and intervention, fostering the adoption of eczema therapeutics and driving market expansion.

Eczema is a chronic condition that can significantly impact a person's quality of life. The constant itching, discomfort, and the potential for skin infections drive individuals to seek solutions that provide relief and long-term management. This demand for effective treatments encourages pharmaceutical companies and researchers to invest in the development of innovative therapies.

Key Market Challenges

Diverse Patient Population

One of the primary challenges faced by the eczema therapeutics market is the diverse nature of the patient population. Eczema can manifest differently in individuals, with varying triggers and severity levels. Tailoring treatments to the specific needs of each patient can be complex and requires a personalized approach. Pharmaceutical companies are increasingly investing in research to address this challenge by developing more targeted therapies.

Key Market Trends

Biologic Therapies Revolutionizing Treatment

Biologic drugs have already made a significant impact on the eczema therapeutics market, but their potential is far from exhausted. In the coming years, we can expect to see the development of more targeted and efficient biologics that offer even better results with fewer side effects. These innovative therapies are likely to become more accessible to a broader range of eczema patients.

Key Market Players

• Sanofi SA
• Encore Dermatology Inc.
• AbbVie Inc.
• F Hoffmann-La Roche AG
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• GSK PLC
• AstraZeneca PLC
• Pfizer Inc.

Report Scope:

In this report, the Global Eczema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Eczema Therapeutics Market, By Treatment:

• Antibiotics
• Antihistamines
• Calcineurin Inhibitors
• Corticosteroids
• Emollients & Moisturizers
• Immunomodulators
• Interleukin Inhibitors

Eczema Therapeutics Market, By Distribution Channel:

• Hospital & Clinics
• Online Pharmacies
• Retail Pharmacies

Eczema Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Eczema Therapeutics Market.

Available Customizations:

Global Eczema Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Eczema Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 5.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Eczema Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 6.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Eczema Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Eczema Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Eczema Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Distribution Channel

7. Europe Eczema Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 7.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Eczema Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. United Kingdom Eczema Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. France Eczema Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Eczema Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Eczema Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Eczema Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 8.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Eczema Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Japan Eczema Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. India Eczema Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Australia Eczema Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. South Korea Eczema Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Distribution Channel

9. South America Eczema Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 9.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Eczema Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Eczema Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Eczema Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Eczema Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
  • 10.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Eczema Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Eczema Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Eczema Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Distribution Channel
  • 10.3.4. Kuwait Eczema Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment
      • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.6.1. Sanofi SA
  • 14.6.1.1. Business Overview
  • 14.6.1.2. Product Offerings
  • 14.6.1.3. Recent Developments
  • 14.6.1.4. Financials (As Reported)
  • 14.6.1.5. Key Personnel
  • 14.6.1.6. SWOT Analysis
• 14.6.2. Encore Dermatology Inc
• 14.6.3. AbbVie Inc
• 14.6.4. F Hoffmann-La Roche AG
• 14.6.5. Novartis AG
• 14.6.6. Regeneron Pharmaceuticals Inc
• 14.6.7. Astellas Pharma Inc
• 14.6.8. GSK PLC
• 14.6.9. AstraZeneca PLC
• 14.6.10. Pfizer Inc

15. Strategic Recommendations

16. About Us & Disclaimer